Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Steeve Néron | Chief Commercial Officer | 201.07k | -- | -- |
| Mr. André Rancourt B.Sc. | Co-Founder | -- | -- | -- |
| Ms. Leslie Auld CPA, M.B.A. | Chief Financial Officer | -- | -- | -- |
| Jennifer McCaughey | Vice President of Investor Relations | -- | -- | -- |
| Ms. Dania Scott B.Sc. | Senior Vice President of Commercial Strategy | -- | -- | -- |
| Ms. Aurelia De Pauw | Senior VP of Clinical Programs & Medical Affairs | -- | -- | -- |
| Mr. Richard Giguere | Chief Executive Officer of Tetra Natural Health Inc. | -- | -- | -- |
| Randy Ringuette | Project Director & Member of Advisory Board | -- | -- | -- |
| Mr. Chris MacLean | Chief Operating Officer of Tetra Natural Health | -- | -- | -- |
Tetra Bio-Pharma Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 33
Description
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available